文献

J-GLOBAL ID：201702214794418060   整理番号：17A0254237

再発性悪性グリオーマに対するテモゾロミドとニムスチン化学療法の第I/II相研究: 京都神経腫瘍学グループ

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

著者 (10件)： AOKI Tomokazu (Department of Neurosurgery, National Hospital Organization, Kyoto Medical Center) ,  ARAKAWA Yoshiki (Department of Neurosurgery, Graduate School of Medicine, Kyoto University) ,  UEBA Tetsuya (Department of Neurosurgery, Kochi Medical School, Kochi University) ,  ODA Masashi (Department of Neurosurgery, National Hospital Organization, Himeji Medical Center) ,  NISHIDA Namiko (Department of Neurosurgery, Kitano Hospital Medical Research Institute) ,  AKIYAMA Yukinori (Department of Neurosurgery, Sapporo Medical University) ,  TSUKAHARA Tetsuya (Department of Neurosurgery, National Hospital Organization, Kyoto Medical Center) ,  IWASAKI Koichi (Department of Neurosurgery, Kitano Hospital Medical Research Institute) ,  MIKUNI Nobuhiro (Department of Neurosurgery, Sapporo Medical University) ,  MIYAMOTO Susumu (Department of Neurosurgery, Graduate School of Medicine, Kyoto University)
資料名： Neurologia Medico-Chirurgica  (Neurologia Medico-Chirurgica)
巻： 57  号： 1  ページ： 17-27(J-STAGE)  発行年： 2017年 
JST資料番号： Z0762A  ISSN： 0470-8105  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： 本第I/II相研究の目的は,テモゾロミド(TMZ)とニムスチ...

シソーラス用語： *神経膠腫 ,...
準シソーラス用語： *悪性グリオーマ ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0254237&from=J-GLOBAL&jstjournalNo=Z0762A") }}

著者キーワード (4件)： temozolomide ,  nimustine ,  recurrent malignant gliomas ,  phase I/II study

分類 (2件)： 腫ようの治療一般  (GE03031L) ,  抗腫よう薬の臨床への応用  (GW16020L)

物質索引 (2件)： テモゾロミド ,  ニムスチン

引用文献 (42件)：

• 1) Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-96, 2005
• 2) Le Rhun E, Taillibert S, Chamberlain MC: Anaplastic glioma: current treatment and management. Expert Rev Neurother 15: 601-620, 2015
• 3) Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880, 2009
• 4) Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2009
• 5) Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014

タイトルに関連する用語 (9件)： 再発 ,  悪性グリオーマ ,  テモゾロミド ,  ニムスチン ,  化学療法 ,  研究 ,  京都 ,  神経腫瘍学 ,  グループ